Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
BHV-1400 Targets the non-immunosuppressive, selective depletion of circulating galactose-deficient Iga1 in Iga nephropathy, Biohaven Pharmaceuticals, Inc , Poster at the 4th Annual Targeted Protein Degradation Summit Europe, London, United Kingdom, March 19-21, 2024 (2024)
"I think one of the things that needs to be understood is that a GLP-1 agonist, whether it's for weight loss or diabetes, it is meant to be on for a while, this is a long-term therapy
This is a practical inclusion that most competing platforms do not offer
Each row states what was actually used, in what species, by what route, with the citation and each row that has no evidence says so
sale restricted to research-only contexts
US$ 22.82
US$ 24.53
US$ 25.06
US$ 20.60
